共 308 条
[1]
Walboomers JM(1999)Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 12-19
[2]
Jacobs MV(2010)Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 11 1048-1056
[3]
Manos MM(2009)A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions Cancer Prev Res (Phila) 2 868-878
[4]
de Sanjose S(2012)Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Lancet Oncol 13 89-99
[5]
Quint WG(2012)Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease Infect Agent Cancer 7 38-814
[6]
Alemany L(2009)Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine J Infect Dis 199 805-2145
[7]
Geraets DT(2006)Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women Pediatrics 118 2135-571
[8]
Klaustermeier JE(2007)Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant J Adolesc Health 40 564-e17
[9]
Lloveras B(2016)Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models Lancet Public Health 1 e8-603
[10]
Tous S(2020)Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries Lancet 395 591-590